Unicycive Therapeutics to Present at the H.C. Wainwright 4th Annual Kidney Virtual Conference

Rhea-AI Summary

Unicycive Therapeutics (Nasdaq: UNCY), a clinical-stage biotech company focused on kidney disease treatments, has announced its participation in the upcoming H.C. Wainwright 4th Annual Kidney Virtual Conference. The company's CEO, Dr. Shalabh Gupta, will engage in a fireside chat on July 14, 2025, at 11:00 AM ET.

Investors and interested parties can access the webcast through the Events and Presentations section of Unicycive's website under the Investors tab.

News Market Reaction – UNCY

+1.96%

+1.96% Session move

In the trading session that priced this news, UNCY gained 1.96%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

LOS ALTOS, Calif., July 07, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that Shalabh Gupta, M.D., Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 4th Annual Kidney Virtual Conference on Monday, July 14, 2025 at 11 a.m. ET.

A link to the webcast may be accessed on the Unicycive website under the Investors section: Events and Presentations.

About Unicycive Therapeutics

Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead investigational treatment is oxylanthanum carbonate, a novel phosphate binding agent for the treatment of hyperphosphatemia in patients with chronic kidney disease who are on dialysis. Unicycive’s second investigational treatment UNI-494 is intended for the treatment of conditions related to acute kidney injury. It has been granted orphan drug designation (ODD) by the FDA for the prevention of Delayed Graft Function (DGF) in kidney transplant patients and has completed a Phase 1 dose-ranging safety study in healthy volunteers. For more information, please visit Unicycive.com and follow us on LinkedIn and X.

Investor Contact:

Kevin Gardner
LifeSci Advisors
kgardner@lifesciadvisors.com

Media Contact:
Rachel Visi
Real Chemistry
redery@realchemistry.com

SOURCE: Unicycive Therapeutics, Inc.

FAQ

When is Unicycive Therapeutics (UNCY) presenting at the H.C. Wainwright Kidney Conference?

Unicycive's CEO will present at a fireside chat on Monday, July 14, 2025 at 11:00 AM ET.

How can investors access Unicycive's (UNCY) presentation at the H.C. Wainwright conference?

Investors can access the webcast through the Events and Presentations section of Unicycive's website under the Investors tab.

Who will be presenting for Unicycive (UNCY) at the H.C. Wainwright Kidney Conference?

Dr. Shalabh Gupta, Unicycive's Chief Executive Officer, will participate in a fireside chat at the conference.

What type of company is Unicycive Therapeutics (UNCY)?

Unicycive is a clinical-stage biotechnology company that develops therapies for patients with kidney disease.